Potassium and Heart Rhythm

The heart is among the most electrically active organs in the body, generating and conducting electrical impulses with remarkable precision approximately 100,000 times per day. Potassium is the single most important ion governing cardiac electrical activity. The concentration of potassium in the extracellular fluid, normally maintained between 3.5 and 5.0 mEq/L, determines the resting membrane potential of cardiac myocytes and influences every phase of the cardiac action potential. Even modest deviations from the normal range can produce clinically significant disturbances in heart rhythm, ranging from benign premature beats to lethal ventricular fibrillation.

The Cardiac Action Potential

Understanding the role of potassium in cardiac rhythm requires familiarity with the cardiac action potential, which differs significantly from the action potential of neurons and skeletal muscle in both duration and ionic basis.

• Phase 0 – Rapid depolarization – The action potential begins with the rapid opening of voltage-gated sodium channels (Nav1.5), producing the steep upstroke of depolarization. Although sodium is the primary current in this phase, the resting membrane potential set by potassium determines the availability of sodium channels and therefore the velocity and amplitude of the upstroke.
• Phase 1 – Early repolarization – A transient outward potassium current (Ito) produces a brief partial repolarization, creating the characteristic "notch" in the action potential waveform. The Ito current is particularly prominent in epicardial and Purkinje fiber cells and contributes to the transmural dispersion of repolarization.
• Phase 2 – Plateau – The plateau phase, unique to cardiac muscle, results from a balance between inward calcium current (ICaL) through L-type calcium channels and outward potassium currents. The delayed rectifier potassium currents (IKr and IKs) gradually increase during this phase, eventually tilting the balance toward repolarization. The plateau phase is responsible for the long duration of the cardiac action potential (200–400 milliseconds) and the prolonged refractory period that prevents tetanic contraction of the heart.
• Phase 3 – Final repolarization – Rapid repolarization occurs as calcium channels inactivate and the delayed rectifier potassium currents (IKr and IKs) reach their peak. The inward rectifier potassium current (IK1) also contributes to terminal repolarization, driving the membrane potential back toward its resting value. Phase 3 is the most potassium-sensitive phase and the one most affected by abnormal serum potassium levels.
• Phase 4 – Resting membrane potential – In working atrial and ventricular myocytes, the resting membrane potential is maintained at approximately −85 to −90 mV by the strong inward rectifier potassium current (IK1). In pacemaker cells of the sinoatrial and atrioventricular nodes, phase 4 is characterized by spontaneous slow depolarization (the pacemaker potential), driven by the funny current (If), calcium currents, and declining potassium currents.

Resting Membrane Potential

The resting membrane potential of cardiac cells is determined primarily by the ratio of intracellular to extracellular potassium concentration, as described by the Nernst equation. Under normal conditions, the intracellular potassium concentration is approximately 140–150 mEq/L, while the extracellular concentration is 3.5–5.0 mEq/L, yielding a resting potential of approximately −90 mV.

• Hypokalemia and the resting potential – When extracellular potassium falls, the Nernst equation predicts membrane hyperpolarization (a more negative resting potential). However, in practice, hypokalemia also reduces the conductance of the IK1 channel, which paradoxically makes the resting potential less stable and more susceptible to ectopic depolarization. The net effect is an increase in cardiac excitability and automaticity.
• Hyperkalemia and the resting potential – Elevated extracellular potassium shifts the resting membrane potential toward less negative values (depolarization). Mild depolarization (resting potential of −80 to −75 mV) may initially increase excitability, but progressive depolarization (beyond −70 mV) inactivates sodium channels, slowing conduction velocity and eventually rendering cells inexcitable.
• Clinical threshold – The relationship between serum potassium and resting membrane potential is approximately linear within the physiological range. A decrease in serum potassium from 4.0 to 3.0 mEq/L hyperpolarizes the membrane by roughly 5–10 mV, while an increase from 4.0 to 6.0 mEq/L depolarizes it by approximately 10–15 mV.

Hypokalemia and Arrhythmias

Hypokalemia (serum potassium below 3.5 mEq/L) is one of the most common electrolyte abnormalities in clinical practice and is a well-established risk factor for cardiac arrhythmias.

• Prolonged repolarization – Hypokalemia reduces the conductance of the delayed rectifier potassium channels (particularly IKr), slowing phase 3 repolarization and prolonging the action potential duration. This manifests on the ECG as QT interval prolongation and increases the susceptibility to early afterdepolarizations (EADs), which are abnormal depolarizations that occur during the prolonged repolarization phase.
• Increased automaticity – Low extracellular potassium enhances the rate of spontaneous phase 4 depolarization in latent pacemaker cells (Purkinje fibers), promoting ectopic beat formation. This can manifest as premature ventricular complexes (PVCs), atrial premature beats, or accelerated junctional rhythms.
• Triggered activity – Early afterdepolarizations caused by hypokalemia can trigger sustained tachyarrhythmias. When an EAD reaches threshold, it initiates a new action potential, which may itself produce another EAD, creating a self-perpetuating cycle known as triggered activity. This mechanism underlies torsades de pointes, a polymorphic ventricular tachycardia that is the hallmark arrhythmia of hypokalemia.
• Re-entry circuits – Hypokalemia creates heterogeneity in repolarization across the myocardium because different regions and cell types (epicardial, endocardial, mid-myocardial) are affected to varying degrees. This dispersion of repolarization provides the substrate for re-entrant arrhythmias, in which electrical impulses circulate repeatedly through pathways of variable excitability and refractoriness.
• Digoxin interaction – Hypokalemia markedly increases the toxicity of cardiac glycosides (digoxin). Potassium and digoxin compete for the same binding site on the Na+/K+-ATPase. When extracellular potassium is low, digoxin binding increases, amplifying its inhibition of the pump and promoting intracellular calcium overload, delayed afterdepolarizations, and potentially fatal arrhythmias.

Hyperkalemia Risks

Hyperkalemia (serum potassium above 5.0 mEq/L) poses a different but equally dangerous set of risks to cardiac rhythm. The effects of hyperkalemia on the heart are progressive and dose-dependent.

• Mild hyperkalemia (5.5–6.0 mEq/L) – Initial effects include increased membrane excitability due to mild depolarization toward the threshold potential. Clinically, this may produce peaked, narrow-based T waves on the ECG, reflecting accelerated repolarization. Many patients at this level are asymptomatic.
• Moderate hyperkalemia (6.0–7.0 mEq/L) – Progressive sodium channel inactivation reduces conduction velocity throughout the heart. The PR interval prolongs as atrioventricular conduction slows, and the QRS complex widens as intraventricular conduction is impaired. P waves may diminish in amplitude or disappear altogether as atrial myocytes become inexcitable (sinoventricular rhythm).
• Severe hyperkalemia (above 7.0 mEq/L) – Profound depolarization renders large portions of the myocardium inexcitable. The widened QRS merges with the T wave to form a sinusoidal pattern, which is a pre-terminal rhythm that can degenerate into ventricular fibrillation or asystole. Without urgent treatment, cardiac arrest and death follow.
• Rate of change – The rapidity of potassium elevation is as important as the absolute level. Acute hyperkalemia is more dangerous than chronic hyperkalemia at the same serum concentration because the heart has less time to adapt through compensatory changes in channel expression and intracellular buffering.
• Modifying factors – Concurrent hypocalcemia, hyponatremia, and acidosis amplify the cardiac toxicity of hyperkalemia. Calcium stabilizes the cardiac membrane and raises the threshold potential, partially counteracting the depolarizing effect of potassium. This is the rationale for administering intravenous calcium gluconate as the first-line emergency treatment for severe hyperkalemia with ECG changes.

ECG Changes

The electrocardiogram provides a non-invasive window into the effects of potassium on cardiac electrical activity. Characteristic ECG patterns are associated with both hypokalemia and hyperkalemia, though the correlation between serum potassium level and ECG findings is imperfect.

ECG Changes in Hypokalemia

• ST-segment depression – Flattening or depression of the ST segment is one of the earliest ECG findings in hypokalemia, reflecting altered repolarization of ventricular myocytes.
• T-wave flattening or inversion – As potassium falls below 3.0 mEq/L, T waves become progressively flattened and may eventually invert, particularly in the precordial leads.
• U waves – The appearance of prominent U waves (small positive deflections following the T wave) is a hallmark of hypokalemia. U waves are thought to represent delayed repolarization of mid-myocardial M cells or Purkinje fibers. When U waves exceed T waves in amplitude, serum potassium is typically below 2.7 mEq/L.
• QT (QU) interval prolongation – The apparent QT interval lengthens in hypokalemia, often due to fusion of the T and U waves. This prolonged repolarization is the substrate for torsades de pointes.
• Arrhythmias – Severe hypokalemia may produce premature atrial and ventricular complexes, supraventricular tachycardia, ventricular tachycardia (including torsades de pointes), and ventricular fibrillation.

ECG Changes in Hyperkalemia

• Peaked T waves – Tall, narrow, symmetrically peaked T waves are usually the first ECG manifestation of hyperkalemia, typically appearing when serum potassium exceeds 5.5 mEq/L. These reflect the accelerated phase 3 repolarization caused by increased potassium conductance.
• PR interval prolongation – Slowed atrial and atrioventricular nodal conduction produces progressive PR prolongation, which may progress to second- or third-degree heart block.
• P-wave flattening and loss – Depolarization of atrial myocytes reduces P-wave amplitude. Complete loss of P waves produces a "sinoventricular" rhythm in which the sinus impulse is conducted directly through specialized pathways to the ventricles without visible atrial depolarization.
• QRS widening – Slowed intraventricular conduction produces progressive QRS prolongation. The widened QRS may resemble bundle branch block or an intraventricular conduction delay pattern.
• Sine wave pattern – In severe hyperkalemia, the widened QRS merges with the peaked T wave to produce a smooth, undulating sine wave pattern. This is a medical emergency indicating imminent cardiac arrest.

Potassium in Cardiac Care

Maintaining potassium within a safe and optimal range is a cornerstone of cardiac care in both acute and chronic settings.

• Target range in cardiac patients – For patients with heart disease, particularly those with heart failure, acute myocardial infarction, or on antiarrhythmic therapy, the target serum potassium is typically maintained between 4.0 and 5.0 mEq/L. This range minimizes the risk of both hypokalemic and hyperkalemic arrhythmias. Some guidelines recommend a minimum of 4.0 mEq/L for patients with acute coronary syndromes.
• Potassium replacement protocols – Intravenous potassium chloride is the standard treatment for symptomatic or severe hypokalemia (serum K+ below 2.5 mEq/L or with ECG changes). The maximum recommended infusion rate is generally 10–20 mEq/hour through a peripheral line or up to 40 mEq/hour through a central line under continuous cardiac monitoring. Oral potassium chloride (typically 40–80 mEq/day in divided doses) is preferred for less urgent replacement.
• Magnesium co-replacement – Hypomagnesemia frequently coexists with hypokalemia and renders potassium replacement ineffective. Magnesium is required for the normal function of the Na+/K+-ATPase and the ROMK potassium channel in the kidney. Refractory hypokalemia should prompt measurement and correction of serum magnesium, typically with intravenous magnesium sulfate (1–2 grams).
• Emergency treatment of hyperkalemia – The acute management of life-threatening hyperkalemia follows a stepwise approach: (1) intravenous calcium gluconate (10 mL of 10% solution) to stabilize the cardiac membrane; (2) insulin with glucose (10 units regular insulin with 25 grams dextrose) to shift potassium intracellularly; (3) sodium bicarbonate in cases of concurrent acidosis; (4) inhaled beta-agonists (albuterol) for additional transcellular shift; and (5) definitive potassium removal through sodium polystyrene sulfonate, patiromer, sodium zirconium cyclosilicate, or hemodialysis.
• Heart failure considerations – Patients with heart failure frequently receive medications that affect potassium balance in opposing directions: loop diuretics cause potassium wasting, while ACE inhibitors, ARBs, aldosterone antagonists (spironolactone, eplerenone), and sacubitril-valsartan promote potassium retention. Careful balancing of these medications and frequent monitoring of serum potassium are essential to avoid both hypokalemia and hyperkalemia in this vulnerable population.
• Post-cardiac surgery – After cardiac surgery, patients are at heightened risk for arrhythmias, and potassium is aggressively maintained above 4.0 mEq/L. Standardized potassium replacement protocols in cardiac intensive care units have been shown to reduce the incidence of postoperative atrial fibrillation and ventricular arrhythmias.

Electrolyte Monitoring

Accurate and timely monitoring of serum potassium is essential for safe cardiac care and prevention of potassium-related arrhythmias.

• Frequency of monitoring – In hospitalized cardiac patients, serum potassium should be measured at least daily. In critically ill patients, those receiving intravenous potassium replacement, or those with rapidly changing clinical status, more frequent monitoring (every 4–6 hours) is appropriate. Outpatients on medications that affect potassium levels should have serum potassium checked within 1–2 weeks of starting or adjusting doses, and at least every 3–6 months thereafter.
• Sample handling – Pseudohyperkalemia, a falsely elevated potassium result caused by in vitro hemolysis or prolonged tourniquet application, is a common source of error. Proper phlebotomy technique, avoidance of excessive fist clenching, and prompt processing of blood samples are essential for accurate results. When a potassium result is unexpectedly elevated, the sample should be repeated before initiating treatment.
• Concurrent electrolyte assessment – Potassium should never be evaluated in isolation. Serum sodium, magnesium, calcium, phosphate, bicarbonate, and renal function (creatinine, BUN) provide critical context. Hypomagnesemia and hypocalcemia amplify the cardiac effects of potassium abnormalities and must be identified and corrected concurrently.
• Point-of-care testing – Point-of-care blood gas analyzers can provide rapid potassium results within minutes, which is invaluable in emergency settings where treatment decisions for hyperkalemia or hypokalemia cannot wait for laboratory turnaround. These instruments measure potassium in whole blood using ion-selective electrodes and generally correlate well with laboratory serum values, though systematic differences of 0.1–0.4 mEq/L may exist.
• Continuous monitoring advances – Research is ongoing into wearable and implantable sensors capable of continuous or near-continuous potassium monitoring. Such technology could provide early warning of dangerous potassium shifts in high-risk patients, particularly those with end-stage renal disease, severe heart failure, or recurrent arrhythmias. Although not yet in routine clinical use, interstitial potassium sensors and potassium-selective micro-electrodes represent a promising frontier in electrolyte monitoring.